TriSalus Life Sciences announced the launch of the TriNav LV Infusion System and TriGuide Guiding Catheter, expanding its portfolio of Pressure-Enabled Drug Delivery (PEDD) devices. The TriNav LV Infusion System is specifically designed for larger vessels, ranging from 3.5 mm to 5.0 mm, which increases the number of patients eligible for the company's PEDD technology.
The new TriGuide Guiding Catheters feature a larger inner diameter, lubricious inner lining, and a reverse curve design to support femoral access for the TriNav LV system, enhancing procedural efficiency. These new products are eligible for the same HCPCS reimbursement codes, C9797 for procedures and C1982 for devices, as existing TriNav products, ensuring seamless integration into current billing structures.
In a limited market release, physicians reported a 97% satisfaction rate with the TriNav LV Infusion System, underscoring its clinical effectiveness and ease of use. This expansion is expected to meaningfully broaden the company's addressable market and provide full access to the $375 million liver embolization market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.